Cost of nosocomial infection

Relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections

Douglas S. Wakefield, Charles M. Helms, R. Michael Massanari, Motomi (Tomi) Mori, Michael Pfaller

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

This study reports an analysis of the relative importance of laboratory antibiotic, and per diem costs of caring for 58 patients with serious Staphylococcus aureus nosocomial infections. Laboratory costs accounted for 2%, antibiotics for 21%, and per diem costs for 77% of total infection-related costs. Only 45% of patients were hospitalized for additional days specifically because of infection, but these patients stayed an average of 18 extra days. Nosocomial infections with S. aureus resistant to penicillinase-resistant penicillins (PRP) were more frequently associated with additional infection-related days of hospitalization than were PRP-susceptible infections. The cost of PRP-resistant infections was also significantly greater than PRP-susceptible infections, primarily because of the costs of additional days of hospitalization. Rational strategies to control costs of nosocomial infection should focus on two approaches: (1) prevention and (2) reduction of acute hospital days attributable to infections.

Original languageEnglish (US)
Pages (from-to)185-192
Number of pages8
JournalAJIC: American Journal of Infection Control
Volume16
Issue number5
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Cross Infection
Staphylococcus aureus
Penicillinase
Anti-Bacterial Agents
Costs and Cost Analysis
Penicillins
Infection
Hospitalization
Cost Control

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases

Cite this

Cost of nosocomial infection : Relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. / Wakefield, Douglas S.; Helms, Charles M.; Massanari, R. Michael; Mori, Motomi (Tomi); Pfaller, Michael.

In: AJIC: American Journal of Infection Control, Vol. 16, No. 5, 1988, p. 185-192.

Research output: Contribution to journalArticle

@article{4e89a3726ece44fd97263d72026c989c,
title = "Cost of nosocomial infection: Relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections",
abstract = "This study reports an analysis of the relative importance of laboratory antibiotic, and per diem costs of caring for 58 patients with serious Staphylococcus aureus nosocomial infections. Laboratory costs accounted for 2{\%}, antibiotics for 21{\%}, and per diem costs for 77{\%} of total infection-related costs. Only 45{\%} of patients were hospitalized for additional days specifically because of infection, but these patients stayed an average of 18 extra days. Nosocomial infections with S. aureus resistant to penicillinase-resistant penicillins (PRP) were more frequently associated with additional infection-related days of hospitalization than were PRP-susceptible infections. The cost of PRP-resistant infections was also significantly greater than PRP-susceptible infections, primarily because of the costs of additional days of hospitalization. Rational strategies to control costs of nosocomial infection should focus on two approaches: (1) prevention and (2) reduction of acute hospital days attributable to infections.",
author = "Wakefield, {Douglas S.} and Helms, {Charles M.} and Massanari, {R. Michael} and Mori, {Motomi (Tomi)} and Michael Pfaller",
year = "1988",
doi = "10.1016/0196-6553(88)90058-2",
language = "English (US)",
volume = "16",
pages = "185--192",
journal = "American Journal of Infection Control",
issn = "0196-6553",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Cost of nosocomial infection

T2 - Relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections

AU - Wakefield, Douglas S.

AU - Helms, Charles M.

AU - Massanari, R. Michael

AU - Mori, Motomi (Tomi)

AU - Pfaller, Michael

PY - 1988

Y1 - 1988

N2 - This study reports an analysis of the relative importance of laboratory antibiotic, and per diem costs of caring for 58 patients with serious Staphylococcus aureus nosocomial infections. Laboratory costs accounted for 2%, antibiotics for 21%, and per diem costs for 77% of total infection-related costs. Only 45% of patients were hospitalized for additional days specifically because of infection, but these patients stayed an average of 18 extra days. Nosocomial infections with S. aureus resistant to penicillinase-resistant penicillins (PRP) were more frequently associated with additional infection-related days of hospitalization than were PRP-susceptible infections. The cost of PRP-resistant infections was also significantly greater than PRP-susceptible infections, primarily because of the costs of additional days of hospitalization. Rational strategies to control costs of nosocomial infection should focus on two approaches: (1) prevention and (2) reduction of acute hospital days attributable to infections.

AB - This study reports an analysis of the relative importance of laboratory antibiotic, and per diem costs of caring for 58 patients with serious Staphylococcus aureus nosocomial infections. Laboratory costs accounted for 2%, antibiotics for 21%, and per diem costs for 77% of total infection-related costs. Only 45% of patients were hospitalized for additional days specifically because of infection, but these patients stayed an average of 18 extra days. Nosocomial infections with S. aureus resistant to penicillinase-resistant penicillins (PRP) were more frequently associated with additional infection-related days of hospitalization than were PRP-susceptible infections. The cost of PRP-resistant infections was also significantly greater than PRP-susceptible infections, primarily because of the costs of additional days of hospitalization. Rational strategies to control costs of nosocomial infection should focus on two approaches: (1) prevention and (2) reduction of acute hospital days attributable to infections.

UR - http://www.scopus.com/inward/record.url?scp=0023755585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023755585&partnerID=8YFLogxK

U2 - 10.1016/0196-6553(88)90058-2

DO - 10.1016/0196-6553(88)90058-2

M3 - Article

VL - 16

SP - 185

EP - 192

JO - American Journal of Infection Control

JF - American Journal of Infection Control

SN - 0196-6553

IS - 5

ER -